Sales revenues were higher by RON2.4 million after the first three months of 2016, reaching RON55 million.
Antibiotice Iasi registered 4% higher sales on external markets in the first quarter of 2016, compared with the same interval a year before. Of $5.9 million cashed, 30% comes from Europe, 22% form Asia and 18% from Africa.
The company paid out a gross dividend per share of RON0.0207 from its 2015 profit, which is equal to a yield of 4.15%.
Antibiotice Iasi reported a net profit of RON27.1 million in 2015 and proposed the payment of dividends worth RON13.9 million. The company’s 2014 profit reached RON31.1 million.
Antibiotice is majority-owned by Romania’s Health Ministry, with a 53% stake, regional investment fund SIF Oltenia holds a 13.5% stake, and the remaining shares are distributed among other shareholders on the local capital market, among which investment funds Broadhurst Investments Limited, SIF Transilvania and SIF Banat-Crisana, as well as pension funds Alico, AZT Viitorul Tau/Allianz and Aripi/Generali.